French pharma major Sanofi (Euronext: SAN) and US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) have received marketing authorization in Canada for Kevzara (sarilumab), making this the first approval for the drug.
The drug is the product of a long-standing global, strategic collaboration between the two companies to discover, develop and commercialize fully human monoclonal antibodies.
Kevzara is used for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to other treatments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze